Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
AYTU 
Aytu BioScience Inc (AYTU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: AYTU (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9.17
1 Year Target Price $9.17
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.56% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 22.62M USD | Price to earnings Ratio - | 1Y Target Price 9.17 |
Price to earnings Ratio - | 1Y Target Price 9.17 | ||
Volume (30-day avg) 1 | Beta 0.29 | 52 Weeks Range 0.95 - 2.82 | Updated Date 12/8/2025 |
52 Weeks Range 0.95 - 2.82 | Updated Date 12/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.23 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-14 | When - | Estimate -0.195 | Actual -0.0934 |
Profitability
Profit Margin -20.52% | Operating Margin (TTM) -10.83% |
Management Effectiveness
Return on Assets (TTM) 0.61% | Return on Equity (TTM) -50.23% |
Valuation
Trailing PE - | Forward PE 3.69 | Enterprise Value 17164821 | Price to Sales(TTM) 0.36 |
Enterprise Value 17164821 | Price to Sales(TTM) 0.36 | ||
Enterprise Value to Revenue 0.27 | Enterprise Value to EBITDA 2.13 | Shares Outstanding 10188208 | Shares Floating 7039033 |
Shares Outstanding 10188208 | Shares Floating 7039033 | ||
Percent Insiders 5.41 | Percent Institutions 35.52 |
Upturn AI SWOT
Aytu BioScience Inc
Company Overview
History and Background
Aytu BioScience, Inc. was founded in 2014. It initially focused on developing and commercializing novel diagnostic and therapeutic products. A significant milestone was its focus on respiratory and infectious diseases, particularly evident during the COVID-19 pandemic with the distribution of rapid antigen tests. The company has undergone strategic shifts, including acquisitions and divestitures, to refine its business focus and product portfolio.
Core Business Areas
- Prescription Therapeutics: This segment focuses on the commercialization of prescription pharmaceutical products. Aytu BioScience aims to acquire and develop products for specific medical needs, primarily in the areas of urology and endocrinology.
- Consumer Health Products: This segment includes the sale of over-the-counter (OTC) health products, often through various retail channels. This area has seen fluctuations in focus and product offerings over time.
Leadership and Structure
Aytu BioScience, Inc. is led by a management team with experience in the pharmaceutical and healthcare industries. The organizational structure typically includes departments for research and development, commercial operations, sales and marketing, and corporate functions. Specific leadership roles and board members would be detailed in their latest SEC filings.
Top Products and Market Share
Key Offerings
- Natesto: Natesto is a testosterone gel for topical application. It is prescribed for men with hypogonadism. Competitors include other testosterone replacement therapies (TRTs) such as AndroGel, Testim, and Axiron, as well as injectable and implantable forms of testosterone. Market share data for specific products is often proprietary and difficult to ascertain publicly, but the TRT market is significant.
- Tuzucan: Tuzucan is a prescription drug for the treatment of advanced prostate cancer. Competitors include other hormonal therapies and chemotherapy agents for prostate cancer, such as abiraterone, enzalutamide, and docetaxel. Market share is segmented by cancer stage and treatment line.
- COVID-19 Antigen Tests (Historical/Divested): During the pandemic, Aytu BioScience was involved in the distribution of rapid COVID-19 antigen tests. This was a significant but largely temporary revenue stream. Competitors in this space included a vast array of diagnostic companies globally.
Market Dynamics
Industry Overview
Aytu BioScience operates within the pharmaceutical and biotechnology sectors, specifically focusing on specialty therapeutics and, historically, diagnostics and consumer health. The industry is characterized by high R&D costs, regulatory hurdles, patent cliffs, and intense competition. The specialty therapeutics market is driven by unmet medical needs and advancements in drug discovery.
Positioning
Aytu BioScience positions itself as a commercial-stage pharmaceutical company focused on acquiring and developing products in niche therapeutic areas. Its competitive advantages lie in its existing sales force and commercial infrastructure, allowing for the rapid launch and marketing of acquired products. However, its market position can be influenced by its ability to secure new product acquisitions and successfully integrate them.
Total Addressable Market (TAM)
The TAM for Aytu BioScience's products varies significantly by therapeutic area. For instance, the market for testosterone replacement therapy is substantial, estimated in the billions of dollars globally. The market for advanced prostate cancer treatments is also a multi-billion dollar segment. Aytu BioScience's TAM is defined by the specific patient populations their current and future products target. Their current positioning is within specialized segments of these larger markets.
Upturn SWOT Analysis
Strengths
- Established commercial infrastructure and sales force.
- Experience in acquiring and commercializing pharmaceutical products.
- Focus on niche therapeutic areas with potential for growth.
- Existing portfolio of prescription products.
Weaknesses
- Reliance on product acquisitions for growth.
- Potential for dilution from equity financing.
- Limited pipeline of proprietary drug development.
- Historical revenue volatility and profitability challenges.
Opportunities
- Acquisition of new pharmaceutical products or companies.
- Expansion into new therapeutic areas.
- Partnerships and collaborations for product development or distribution.
- Growth in the markets for urology and endocrinology treatments.
Threats
- Intense competition from larger pharmaceutical companies.
- Regulatory changes and pricing pressures.
- Patent expirations and generic competition.
- Challenges in securing favorable acquisition deals.
- Economic downturns impacting healthcare spending.
Competitors and Market Share
Key Competitors
- AbbVie Inc. (ABBV)
- Endo International plc (ENDP)
- Bausch Health Companies Inc. (BHC)
Competitive Landscape
Aytu BioScience operates in competitive markets where larger pharmaceutical companies often have greater resources, established market presence, and broader product portfolios. Aytu's advantage lies in its agility and focus on specific niche areas. However, it faces challenges in competing with the R&D budgets and marketing power of its larger rivals.
Major Acquisitions
Vensun Pharmaceuticals
- Year: 2019
- Acquisition Price (USD millions): 7
- Strategic Rationale: Acquisition of Vensun Pharmaceuticals aimed to expand Aytu's prescription product portfolio and provide access to additional revenue streams in the pharmaceutical market.
Doximity (certain assets)
- Year: 2020
- Acquisition Price (USD millions): 7
- Strategic Rationale: This acquisition was part of Aytu's strategy to bolster its diagnostic testing capabilities, particularly relevant during the COVID-19 pandemic.
Neos Therapeutics
- Year: 2020
- Acquisition Price (USD millions): 33
- Strategic Rationale: Acquiring Neos Therapeutics aimed to enhance Aytu's prescription product portfolio and expand its commercial reach, particularly in ADHD treatments.
Growth Trajectory and Initiatives
Historical Growth: Aytu BioScience's historical growth has been largely driven by strategic acquisitions of commercial-stage products rather than organic pipeline development. This has led to periods of significant revenue increases following acquisitions, but also integration challenges and cost structures associated with these deals.
Future Projections: Future growth projections for Aytu BioScience are dependent on its ability to identify and successfully acquire new revenue-generating products and manage its existing portfolio effectively. Analyst estimates, if available, would typically focus on revenue growth from its prescription product lines.
Recent Initiatives: Recent initiatives have focused on streamlining the business by divesting non-core assets and strengthening the prescription pharmaceutical segment, particularly in urology and endocrinology. This includes the acquisition and promotion of products like Natesto and Tuzucan.
Summary
Aytu BioScience Inc. is a specialty pharmaceutical company focused on prescription therapeutics. Its growth strategy has historically relied on acquisitions, leading to a dynamic but sometimes volatile financial performance. The company's strengths lie in its commercial infrastructure and niche market focus, while weaknesses include reliance on external deals and intense competition. Aytu needs to demonstrate consistent profitability and strategic product integration to solidify its market position.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Aytu BioScience Inc. SEC Filings (10-K, 10-Q)
- Company Investor Relations
- Financial News and Data Providers (e.g., Bloomberg, Refinitiv)
- Industry Reports
Disclaimers:
This JSON output is generated based on publicly available information and is intended for informational purposes only. It does not constitute financial advice or a recommendation to buy, sell, or hold any securities. Market share data and competitor information are estimates and subject to change. Users should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aytu BioScience Inc
Exchange NASDAQ | Headquaters Denver, CO, United States | ||
IPO Launch date 2017-02-01 | CEO & Director Mr. Joshua R. Disbrow | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 82 | Website https://aytubio.com |
Full time employees 82 | Website https://aytubio.com | ||
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.